Sanofi-Aventis announced that an FDA advisory committee will meet March 18 to evaluate Multaq, a drug candidate for atrial fibrillation. The move delays the agency's decision on the medicine, which secured priority-review status in July. Multaq could generate more than $2 billion in yearly sales, some analysts said.

Full Story:
Bloomberg, Reuters

Related Summaries